Kailera Therapeutics, Inc. Common Stock (NASDAQ: KLRA) — Healthcare · Share Price, Chart & Market Data
About: Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $22.47 (-10.41%)
KLRAKailera Therapeutics, Inc. Common Stock
Loading watchlist status…
Trade KLRA now
Kailera Therapeutics, Inc. Common Stock share price
KLRA price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 8:44 am GMT+0
KLRA price performance
-8.696%
5D
-13.577%
1M
-13.577%
YTD
-13.577%
1Y
KLRA price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 8:44 am GMT+0
KLRA details
KLRA Market Signals